189 related articles for article (PubMed ID: 15034023)
1. Genome-wide analysis of molecular changes in IL-12-induced control of mammary carcinoma via IFN-gamma-independent mechanisms.
Shi X; Cao S; Mitsuhashi M; Xiang Z; Ma X
J Immunol; 2004 Apr; 172(7):4111-22. PubMed ID: 15034023
[TBL] [Abstract][Full Text] [Related]
2. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
Wigginton JM; Park JW; Gruys ME; Young HA; Jorcyk CL; Back TC; Brunda MJ; Strieter RM; Ward J; Green JE; Wiltrout RH
J Immunol; 2001 Jan; 166(2):1156-68. PubMed ID: 11145697
[TBL] [Abstract][Full Text] [Related]
3. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.
Hess SD; Egilmez NK; Bailey N; Anderson TM; Mathiowitz E; Bernstein SH; Bankert RB
J Immunol; 2003 Jan; 170(1):400-12. PubMed ID: 12496425
[TBL] [Abstract][Full Text] [Related]
4. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
5. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.
Ostrand-Rosenberg S; Clements VK; Terabe M; Park JM; Berzofsky JA; Dissanayake SK
J Immunol; 2002 Nov; 169(10):5796-804. PubMed ID: 12421960
[TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.
Pulaski BA; Smyth MJ; Ostrand-Rosenberg S
Cancer Res; 2002 Aug; 62(15):4406-12. PubMed ID: 12154047
[TBL] [Abstract][Full Text] [Related]
7. Gene expression analysis in Interleukin-12-induced suppression of mouse mammary carcinoma.
Shi X; Liu J; Xiang Z; Mitsuhashi M; Wu RS; Ma X
Int J Cancer; 2004 Jul; 110(4):570-8. PubMed ID: 15122590
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
9. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy.
Wigginton JM; Gruys E; Geiselhart L; Subleski J; Komschlies KL; Park JW; Wiltrout TA; Nagashima K; Back TC; Wiltrout RH
J Clin Invest; 2001 Jul; 108(1):51-62. PubMed ID: 11435457
[TBL] [Abstract][Full Text] [Related]
10. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis.
duPre' SA; Redelman D; Hunter KW
Exp Mol Pathol; 2008 Dec; 85(3):174-88. PubMed ID: 18929358
[TBL] [Abstract][Full Text] [Related]
11. Global gene expression profiling in interleukin-12-induced activation of CD8(+) cytotoxic T lymphocytes against mouse mammary Carcinoma.
Cao S; Xiang Z; Ma X
Cell Mol Immunol; 2004 Oct; 1(5):357-66. PubMed ID: 16285895
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor activities of IL-27.
Shimizu M; Shimamura M; Owaki T; Asakawa M; Fujita K; Kudo M; Iwakura Y; Takeda Y; Luster AD; Mizuguchi J; Yoshimoto T
J Immunol; 2006 Jun; 176(12):7317-24. PubMed ID: 16751375
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
Hafner M; Falk W; Echtenacher B; Männel DN
Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.
Smyth MJ; Taniguchi M; Street SE
J Immunol; 2000 Sep; 165(5):2665-70. PubMed ID: 10946296
[TBL] [Abstract][Full Text] [Related]
16. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
17. Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.
Guiducci C; Di Carlo E; Parenza M; Hitt M; Giovarelli M; Musiani P; Colombo MP
J Immunol; 2004 Apr; 172(7):4026-36. PubMed ID: 15034014
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
19. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways.
Yu WG; Ogawa M; Mu J; Umehara K; Tsujimura T; Fujiwara H; Hamaoka T
J Leukoc Biol; 1997 Oct; 62(4):450-7. PubMed ID: 9335314
[TBL] [Abstract][Full Text] [Related]
20. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
